---
title: "TPST.US (TPST.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TPST.US/news.md"
symbol: "TPST.US"
name: "TPST.US"
parent: "https://longbridge.com/en/quote/TPST.US.md"
datetime: "2026-05-21T17:32:44.683Z"
locales:
  - [en](https://longbridge.com/en/quote/TPST.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TPST.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TPST.US/news.md)
---

# TPST.US (TPST.US) — Related News

### [Tempest Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286468845.md)
*2026-05-14T21:05:40.000Z*
### [Tempest Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286465658.md)
*2026-05-14T20:41:37.000Z*
### [TPST Q1'26 Earnings: revenue estimate is 0 USD](https://longbridge.com/en/news/284752602.md)
*2026-04-30T11:00:20.000Z*
> TPST (Tempest Therapeutics, Inc.) will announce its Q1'26 earnings on May 07 at 8:00 AM ET. The revenue estimate for Q1'

### [12 Health Care Stocks Moving In Friday's Intraday Session](https://longbridge.com/en/news/282373826.md)
*2026-04-10T17:05:53.000Z*
> In Friday's trading session, Cue Biopharma saw a significant gain of 69.9%, reaching $0.5, while Plus Therapeutics and T

### [Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33)](https://longbridge.com/en/news/281023009.md)
*2026-03-30T12:45:01.000Z*
> Tempest Therapeutics reported a net loss of $26.3 million for the year, or $(6.33) per share, reflecting a 37% improveme

### [Tempest Therapeutics | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/281022174.md)
*2026-03-30T12:43:11.000Z*
### [Thursday 3/26 Insider Buying Report: RPC, TPST](https://longbridge.com/en/news/280672308.md)
*2026-03-26T17:55:26.000Z*
> On March 26, insider buying activity was reported for RPC and Tempest Therapeutics (TPST). Director David M. McCoy of Ri

### [Top Biotech Insider Quietly Makes a Bold Move That Could Signal What’s Coming Next](https://longbridge.com/en/news/280555342.md)
*2026-03-26T02:10:20.000Z*
> Insider activity at Tempest Therapeutics (TPST) on March 25, 2026, saw CEO Angel Matthew purchase 231,482 shares for $50